This lecture from the iBioSeminars project is presented by Brian Druker of HHMI and the Oregon Health & Science University Cancer Institute. It describes the clinical features and the molecular pathogenesis of the disease for which imatinib was developed, chronic myeloid leukemia (CML). This overview will trace the history of the identification of the target of imatinib, BCR-ABL. The preclinical development of the BCR-ABL kinase inhibitor, imatinib and highly successful clinical trials of this agent for patients with CML will be reviewed along with the most up-to-date follow-up on these studies. This video is the first of three, running 33:54 minutes and can be downloaded in QuickTime, MP4, M4V, or PDF formats. It can also be streamed on iTunes or YouTube.
(no comments available yet for this resource)